Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             168 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A comparison of phenelzine and its N-acetylated analogue in the elevated plus-maze test Baker, G.B.
 1996
 6 Supplement 4 p. 55-
1 p.
 artikel
2 A controlled trial with ORG 2766, an ACTH-(4–9) analog, in 50 relatively able children with autism Buitelaar, Jan K.
 1996
 6 Supplement 4 p. 13-19
7 p.
 artikel
3 Acute, subchronic and discontinuation effects of zopiclone on sleep EEG and nocturnal melatonin secretion Mann, K.
 1996
 6 Supplement 4 p. 163-168
6 p.
 artikel
4 Adjunctive therapy in severe depression Dinan, T.G.
 1996
 6 Supplement 4 p. S4-4-
1 p.
 artikel
5 A double-blind, assessment of carteolol, in the treatment of neuroleptic-induced akathisia Aoba, A.
 1996
 6 Supplement 4 p. 72-
1 p.
 artikel
6 Analgesic effect of l-threo-3,4-dihydroxyphenylserine (L-DOPS) in patients with chronic pain Takagi, Hiroshi
 1996
 6 Supplement 4 p. 43-47
5 p.
 artikel
7 Anhedonia and depression in chronic schizophrenia: Distinct or overlapping constructs? Loas, G.
 1996
 6 Supplement 4 p. 62-
1 p.
 artikel
8 Animal models of circadian disorders and their treatment with chronobiotics Redman, J.R.
 1996
 6 Supplement 4 p. 34-
1 p.
 artikel
9 An inventory of chronic, mentally disabled schizophrenic outpatients Flyckt, L.K.
 1996
 6 Supplement 4 p. 65-
1 p.
 artikel
10 Antibodies to serotonin and cathecholamines as neuroimmunumodulators in experimental opiate addiction Basharova, L.A.
 1996
 6 Supplement 4 p. S4-130-
1 p.
 artikel
11 Antidepressants in the treatment of depressive syndrome in schizophrenia Jašović-Gašić, M.
 1996
 6 Supplement 4 p. 202-
1 p.
 artikel
12 Antidepressive properties of indeloxazine hydrochloride, a cerebral activator Yamamoto, M.
 1996
 6 Supplement 4 p. 49-
1 p.
 artikel
13 Anxiolytic effects found in the fear-potentiated startle response paradigm are not due to a non-specific disruption of startle behavior Joordens, R.J.E.
 1996
 6 Supplement 4 p. S4-145-S4-146
NaN p.
 artikel
14 AP521, a novel benzothieno-pyridine derivative, shows anxiolytic activity Nagatani, Tadashi
 1996
 6 Supplement 4 p. 116-
1 p.
 artikel
15 Author index 1996
 6 Supplement 4 p. S4-169-S4-174
NaN p.
 artikel
16 Benzodiazepine binding in T-lymphocytes from parkinsonian patients Bongioanni, P.
 1996
 6 Supplement 4 p. S4-96-S4-97
NaN p.
 artikel
17 Calciumantagonism as a common mode of action of some antiepileptic drugs in the treatment of epilepsies and affective disorders Walden, J.
 1996
 6 Supplement 4 p. 98-
1 p.
 artikel
18 Calcium channel biocker felodipine and motor activity of spinal cord injured rabbits Draganic, P.
 1996
 6 Supplement 4 p. 195-
1 p.
 artikel
19 cAMP signal cascade in postmortem brains of depressives and suicides Ozawa, H.
 1996
 6 Supplement 4 p. 212-
1 p.
 artikel
20 Can panic disorder patients treated with more than 4 mg/day of alprazolam reduce their dose? Corrigan, M.
 1996
 6 Supplement 4 p. 113-
1 p.
 artikel
21 Cardiac tolerability of trimipramine in the elderly Malsch, C.
 1996
 6 Supplement 4 p. 6-
1 p.
 artikel
22 CCK-4 in cerebrospinal fluid: A pilot study in healthy male volunteers Gunnarsson, T.
 1996
 6 Supplement 4 p. 113-
1 p.
 artikel
23 CCK-4-induced calcium mobilization in T cells is enhanced in panic disorder Akiyoshi, J.
 1996
 6 Supplement 4 p. 114-
1 p.
 artikel
24 Changes in composition of phospholipids and fatty acids in rat brain during aging Řípovà, D.
 1996
 6 Supplement 4 p. S4-95-S4-96
NaN p.
 artikel
25 Changes of the lymphocyte subset in major depressive disorder and schizophrenia Park, D.B.
 1996
 6 Supplement 4 p. 198-199
2 p.
 artikel
26 Choreoathetoid movements occur spontaneously in never-medicated patients with schizophrenia Hoffman, W.
 1996
 6 Supplement 4 p. 223-
1 p.
 artikel
27 Chronic treatment with eltoprazine does not lead to tolerance in its anti-aggressive action, in contrast to haloperidol Mos, Jan
 1996
 6 Supplement 4 p. 1-7
7 p.
 artikel
28 Clinical trial on antipsychotic effects of the sigma lignad panamesine in schizophrenia Steiger, A.
 1996
 6 Supplement 4 p. 149-
1 p.
 artikel
29 Clocinnamox inhibits heroin-stimulated nucleus accumbens dopamine overflow Zernig, G.
 1996
 6 Supplement 4 p. 69-
1 p.
 artikel
30 Cocaine psychosis and addiction: A role for sensitization and search for substrates Bartler, E.
 1996
 6 Supplement 4 p. 156-
1 p.
 artikel
31 Cognitive impairment and tardive dyskinesia Shriqui, C.L.
 1996
 6 Supplement 4 p. 132-
1 p.
 artikel
32 Combination of clozazpine and SSRIS in schizophrenic patients Hiemke, C.
 1996
 6 Supplement 4 p. 217-
1 p.
 artikel
33 Combined cognitive-behavioral and pharmacotherapy in refractory depression Strauss, W.H.
 1996
 6 Supplement 4 p. 49-
1 p.
 artikel
34 Comorbidity between obsessive compulsive disorder and unipolar and bipolar disorders Pfanner, C.
 1996
 6 Supplement 4 p. S4-149-
1 p.
 artikel
35 Comorbidity between somatoform disorders and depression Altamura, A.C.
 1996
 6 Supplement 4 p. 18-
1 p.
 artikel
36 Comparison between early- and late-onset rapid cycling affective disorders. -Clinical course and response to pharmacotherapy Fujiwara, Y.
 1996
 6 Supplement 4 p. 183-184
2 p.
 artikel
37 Comparison of brain activity patterns during finger opposition with and without tactile stimulation using a BOLD-fMRI method Jansma, J.M.
 1996
 6 Supplement 4 p. S4-167-
1 p.
 artikel
38 Comparison of effects of paroxetine and amitriptyline on driving and psychomotor performance in depression Starmer, G.
 1996
 6 Supplement 4 p. 142-143
2 p.
 artikel
39 Course of cognitive dysfunction and psychopathology in relation to duration of initially untreated psychosis Waddington, J.L.
 1996
 6 Supplement 4 p. 220-221
2 p.
 artikel
40 D2 dopamine receptor occupancy (IBZM-SPECT) and extrapyramidal symptoms under treatment with risperidone Mager, T.
 1996
 6 Supplement 4 p. S4-102-S4-103
NaN p.
 artikel
41 D2 dopamine receptors in the short- and long-term modulation of corticostriatal transmission Calabresi, P.
 1996
 6 Supplement 4 p. 24-
1 p.
 artikel
42 Developing new antipsychotic drugs and treatment strategies: An overview Copolov, D.L.
 1996
 6 Supplement 4 p. 24-
1 p.
 artikel
43 Dexamethasone augmentation of sertraline response in resistant depression Dinan, T.
 1996
 6 Supplement 4 p. 126-127
2 p.
 artikel
44 Different traits of personality and Cloninger's types of alcoholism Hadjichristos, A.
 1996
 6 Supplement 4 p. S4-137-
1 p.
 artikel
45 Disturbances of one-carbon metabolism in schizophrenia Regland, B.
 1996
 6 Supplement 4 p. 175-
1 p.
 artikel
46 Does severe depression have a different pharmacology? Aschauer, H.N.
 1996
 6 Supplement 4 p. S4-3-S4-4
NaN p.
 artikel
47 Dose ranging study comparing 4 doses of sertindole and 1 dose of haloperidol in schizophrenic patients Hale, A.
 1996
 6 Supplement 4 p. 61-
1 p.
 artikel
48 Duration of initially untreated psychosis, negative symptoms and cognitive impairment in schizophrenia Scully, P.J.
 1996
 6 Supplement 4 p. 135-
1 p.
 artikel
49 ECNP - Lilly Awards 1996 1996
 6 Supplement 4 p. 333-334
2 p.
 artikel
50 Effectiveness of glutamate agonist on negative symptoms of schizophrenia Lenzi, A.
 1996
 6 Supplement 4 p. 201-
1 p.
 artikel
51 Effect of a major depressive episode history on the CCK-4 response in women Le Mélledo, J.-M.
 1996
 6 Supplement 4 p. 113-114
2 p.
 artikel
52 Effect of “Kangenkaryu” on cerebral blood flow and gene expression in rat Sugaya, K.
 1996
 6 Supplement 4 p. 192-
1 p.
 artikel
53 Effect of rifampin on plasma concentrations and clinical responses of haloperidol in schizophrenics Woo, J.I.
 1996
 6 Supplement 4 p. 37-
1 p.
 artikel
54 Effect of vasopressine on C1-uptake in cultured astroglis Katay, L.
 1996
 6 Supplement 4 p. 195-
1 p.
 artikel
55 Effects of clozapine on medial prefrontal cortical cells: A presynaptical hypothesis Gobbi, G.
 1996
 6 Supplement 4 p. S4-117-
1 p.
 artikel
56 Effects of H-CRH on sleep and body temperature rhythms Hirano, T.
 1996
 6 Supplement 4 p. 79-
1 p.
 artikel
57 Effects of imidazoline2 receptor ligands on neuronal damage in global ischaemia in the rat Graven, J.A.
 1996
 6 Supplement 4 p. 76-
1 p.
 artikel
58 Effects of zolpidem, triazolam and zopiclone on REM sleep and hippocampal theta activity in rats Yoshimoto, M.
 1996
 6 Supplement 4 p. 101-
1 p.
 artikel
59 Efficacy and safety of fluoxetine in major depression Çetin, M.
 1996
 6 Supplement 4 p. S4-71-S4-72
NaN p.
 artikel
60 Efficacy of mirtazapine in moderate and severe depression Pinder, R.M.
 1996
 6 Supplement 4 p. S4-62-
1 p.
 artikel
61 Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat Wadenberg, M-L.
 1996
 6 Supplement 4 p. 305-310
6 p.
 artikel
62 Experimental study: Stress and memory Le Poncin, M.
 1996
 6 Supplement 4 p. 110-
1 p.
 artikel
63 Fast feedback: Evidence for the functioning of type II steroid receptors in depression Cooney, J.M.
 1996
 6 Supplement 4 p. 208-
1 p.
 artikel
64 Fluoxetine treatment of comorbid premature ejaculation and panic disorder Kindler, S.
 1996
 6 Supplement 4 p. S4-146-S4-147
NaN p.
 artikel
65 Fluvoxamine effective in preventing recurrence of major depression Terra, J.L.
 1996
 6 Supplement 4 p. S4-65-
1 p.
 artikel
66 GABA-B receptors in memory processes Fröstl, W.
 1996
 6 Supplement 4 p. 30-
1 p.
 artikel
67 Handbook of neurological speech and language disorders Buitelaar, Jan K.
 1996
 6 Supplement 4 p. 261-
1 p.
 artikel
68 Immediate early genes: Functions and responses to drugs Morgan, J.I.
 1996
 6 Supplement 4 p. S4-27-S4-28
NaN p.
 artikel
69 Immune and acute phase responses in treatment resistant depression Maes, Michael
 1996
 6 Supplement 4 p. 226-
1 p.
 artikel
70 Impact of stress-factors of technical accident on emotional sphere of children Chustrak, A.
 1996
 6 Supplement 4 p. 12-
1 p.
 artikel
71 Increased oxidative stress in alcohol dependent patients as estimated by the in vivo acetylsalicylic acid assay (ASAA) Thome, J.
 1996
 6 Supplement 4 p. S4-138-
1 p.
 artikel
72 Increase of GABA-B responses by carbamazepine as a mechanism of action in affective disorders von Wegerer, J.
 1996
 6 Supplement 4 p. 56-
1 p.
 artikel
73 Is clozapine a dopaminergic drug? Tang, S.W.
 1996
 6 Supplement 4 p. 105-
1 p.
 artikel
74 L-4 Focusing on serotonin for the action of drugs effective in mood disorders: pre-synaptic versus postsynaptic mechanisms Nutt, D.J.
 1996
 6 Supplement 4 p. S2-S3
2 p.
 artikel
75 Linkage study of narcolepsy in 7 Japanese families Himei, A.
 1996
 6 Supplement 4 p. 102-
1 p.
 artikel
76 Lipoxygenase pathway modulation of dopamine release Davidson, B.
 1996
 6 Supplement 4 p. 108-
1 p.
 artikel
77 Long-term changes induced by anti-depressant drugs in the presynaptic release machinery Popoli, M.
 1996
 6 Supplement 4 p. 145-146
2 p.
 artikel
78 Long term treatment of panic disorder-agoraphobia Perugi, G.
 1996
 6 Supplement 4 p. 82-
1 p.
 artikel
79 Low serum cholesterol, serotonin and suicidal behavior Pitchot, W.
 1996
 6 Supplement 4 p. S4-67-
1 p.
 artikel
80 Maintenance of calcium-mediated metabolic control as a therapeutic principle in energy-compromised neurological disorders Heininger, K.
 1996
 6 Supplement 4 p. S4-98-
1 p.
 artikel
81 Mania secondary to HIV infection Ellen, S.
 1996
 6 Supplement 4 p. 9-
1 p.
 artikel
82 Measurement of lithium brain concentration by Li-7 MRS and correlation with effects Kato, T.
 1996
 6 Supplement 4 p. 82-
1 p.
 artikel
83 Mechanical lesions of the fimbria fornix in rat brain studied by 1H-magnetic resonance imaging. Evidence for long-lasting dynamic alterations in the ipsilateral ventricular system Dijkhuizen, Rick M.
 1996
 6 Supplement 4 p. 21-27
7 p.
 artikel
84 Medication choices in maintenance antipsychotic therapy: Theory and clinical practice Remington, Gary
 1996
 6 Supplement 4 p. 85-
1 p.
 artikel
85 Methadone plasma levels in a methadone maintenance treatment Torrens, M.
 1996
 6 Supplement 4 p. 120-
1 p.
 artikel
86 (+)-Mirtazapine and (+)-desmethylmirtazapine levels in rat brain in relation to in vivo blockade of α2 receptors Broekkamp, C.L.E.
 1996
 6 Supplement 4 p. 52-53
2 p.
 artikel
87 Mirtazapine vs tricyclic antidepressants: An overview of efficacy data Sitsen, A.
 1996
 6 Supplement 4 p. 46-
1 p.
 artikel
88 Modification of the method of affective disorder prophylaxis with lithium stalts Kuznestov, V.N.
 1996
 6 Supplement 4 p. 250-
1 p.
 artikel
89 Modulation of drug reward by receptor ligands Zvartau, E.
 1996
 6 Supplement 4 p. S4-4-S4-5
NaN p.
 artikel
90 Molecular genetics of suicidal behavior Mann, J.J.
 1996
 6 Supplement 4 p. 22-
1 p.
 artikel
91 Mood effects of hormonal interventions — Comparisons to conventional antidepressants Freeman, E.W.
 1996
 6 Supplement 4 p. 87-88
2 p.
 artikel
92 Multiple dose pharmacokinetics and dose proportionality study of ‘Seroquel’ (ICI 204,636) in male schizophrenic patients Wong, Y.W.J.
 1996
 6 Supplement 4 p. 38-
1 p.
 artikel
93 Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of renal impairment Wilner, Keith D.
 1996
 6 Supplement 4 p. 41-
1 p.
 artikel
94 Negative symptoms and sertindole Kasper, S.
 1996
 6 Supplement 4 p. S4-13-
1 p.
 artikel
95 Neural cell adhesion molecules and the developmental hypothesis of schizophrenia Srivastava, L.K.
 1996
 6 Supplement 4 p. 170-
1 p.
 artikel
96 Neuroactive steroids acting at GABAA receptors Gee, Kelvin W.
 1996
 6 Supplement 4 p. S4-17-S4-18
NaN p.
 artikel
97 Neuroendocrine correlates and weight gain during treatment with clozapine Bersani, G.
 1996
 6 Supplement 4 p. 209-
1 p.
 artikel
98 Neuroleptic malignant syndrome and psychosis in two siblings with gangliosidosis type II Manor, I.
 1996
 6 Supplement 4 p. S4-119-
1 p.
 artikel
99 Neuroleptic treatment and MRI brain changes in schizophrenia Jarema, M.
 1996
 6 Supplement 4 p. 181-
1 p.
 artikel
100 New day tranquilizer — Tarden Denisenko, P.P.
 1996
 6 Supplement 4 p. 117-
1 p.
 artikel
101 New developments in impulsivity and compulsivity Hollander, E.
 1996
 6 Supplement 4 p. 91-
1 p.
 artikel
102 NMR spectroscopy as a tool for in vivo detection and monitoring of progress of HIV CNS disease Fein, G.
 1996
 6 Supplement 4 p. 31-
1 p.
 artikel
103 Norharman in multiple drug-addicts and healthy controls Fekkes, D.
 1996
 6 Supplement 4 p. S4-129-
1 p.
 artikel
104 Nutrient presentation of cognitive and memory performances Le Poncin, M.
 1996
 6 Supplement 4 p. 187-
1 p.
 artikel
105 Olanzapine versus haloperidol: acute results of the multi-center international trial Tran, P.
 1996
 6 Supplement 4 p. 59-
1 p.
 artikel
106 Panic attacks in chronic schizophrenia a complication of long-term antipsychotic medication Higuchi, H.
 1996
 6 Supplement 4 p. 63-
1 p.
 artikel
107 P-4 Behavioral effects of acute and chronic Moclobemide administrations in mice Akarsu, E.S.
 1996
 6 Supplement 4 p. S12-
1 p.
 artikel
108 P-33 Can antidepressants prevent institutional care? Citalopram in the treatment of elderly depressed patients with and without dementia disorders Koskinen, T.
 1996
 6 Supplement 4 p. S21-S22
2 p.
 artikel
109 P-16 Depression and altered immunity: Clinical implications for immunologic processes Stankovska, G.
 1996
 6 Supplement 4 p. S15-
1 p.
 artikel
110 Peduncular hallucinosis: SSRI efficacy brings new arguments for an old theory Gilles, C.
 1996
 6 Supplement 4 p. S4-94-S4-95
NaN p.
 artikel
111 P-2 Effects of electroconvulsive seizures on protein kinase C-induced potentiation of cyclic AMP response are modified by pretreatment with antidepressant drugs Nalepa, I.
 1996
 6 Supplement 4 p. S11-
1 p.
 artikel
112 Pharmacokinetic-pharmacodynamic modelling of the interaction between phenytoin and sodium valproate Della Paschoa, O.E.
 1996
 6 Supplement 4 p. S4-160-S4-161
NaN p.
 artikel
113 Pharmacological profile of benzodiazepine site ligands with recombinant GABAA receptor subtypes Graham, David
 1996
 6 Supplement 4 p. 119-125
7 p.
 artikel
114 Pharmacological profile of OPC-14523 (1): A novel sigma and 5-HT1A receptor agonist Tottori, K.
 1996
 6 Supplement 4 p. 190-
1 p.
 artikel
115 Platelet serotonin2 receptor binding in affective disorders Tsujimura, T.
 1996
 6 Supplement 4 p. 129-
1 p.
 artikel
116 Positive allosteric modulation of AMPA or GABAAreceptors antagonizes alprazolam induced learning impairment in monkeys Costa, E.
 1996
 6 Supplement 4 p. 152-
1 p.
 artikel
117 Pramipexole in major depression — An open clinical trial Szegedi, A.
 1996
 6 Supplement 4 p. 142-
1 p.
 artikel
118 Prevalence of depressive symptoms in the elderly, a community study Kørner, A.
 1996
 6 Supplement 4 p. 5-
1 p.
 artikel
119 Prevalence of refractory depression and therapeutic strategies in an italian out-patient mental health department Jansen, A.
 1996
 6 Supplement 4 p. S4-120-
1 p.
 artikel
120 Protective effects of anapsos in rats with hippocampal neurodegeneration Alvarez, X.A.
 1996
 6 Supplement 4 p. 75-
1 p.
 artikel
121 P-19 The drug effects pharmacokinetic determinants as a basis for optimal psychotropic drug dosage form prediction Karamisheva, E.I.
 1996
 6 Supplement 4 p. S16-
1 p.
 artikel
122 P-47 The effects of amitriptyline and clomipramine on learning and memory in an elevated plus-maze test in mice Nurten, A.
 1996
 6 Supplement 4 p. S26-
1 p.
 artikel
123 P-50 The effects of flumazenil on two-way active avoidance, in diazepam-treated rats Çelik, Turgay
 1996
 6 Supplement 4 p. S27-
1 p.
 artikel
124 P-64 Working out the system of health protection for persons of intellectual labor Ternovskaya, V.A.
 1996
 6 Supplement 4 p. S32-S33
2 p.
 artikel
125 Quality of life in depression — How should it be measured? Katschnig, H.
 1996
 6 Supplement 4 p. 166-
1 p.
 artikel
126 Rapid treatment of major depression with DMI and fluoxetine Nelson, J.C.
 1996
 6 Supplement 4 p. 220-
1 p.
 artikel
127 Receptor mechanisms of benzodiazepine dependence Potokar, J.
 1996
 6 Supplement 4 p. 159-160
2 p.
 artikel
128 Reduced 5-HT in CSF: Trait or state marker for suicidality? Becker, U.
 1996
 6 Supplement 4 p. S4-79-S4-80
NaN p.
 artikel
129 Regional cerebral perfusion by Tc-99m HMPAO SPECT before and after tacrine in alzheimer's disease Tourtauchaux, R.
 1996
 6 Supplement 4 p. 178-
1 p.
 artikel
130 Regulation of AP-1 transcription complex in the CNS by antipsychotics Rogue, P.
 1996
 6 Supplement 4 p. S4-114-
1 p.
 artikel
131 Relationship between late-onset mania and silent cerebral infarction Fujikawa, T.
 1996
 6 Supplement 4 p. 184-
1 p.
 artikel
132 Responsiveness of rabbit prostate strips to imipramine and trazodone Tita, B.
 1996
 6 Supplement 4 p. S4-83-
1 p.
 artikel
133 Retardation and the classification of major depression Parker, G.
 1996
 6 Supplement 4 p. 153-
1 p.
 artikel
134 Risperidone and reversible neutropenia: A negative rechallenge Bondolfi, Guido
 1996
 6 Supplement 4 p. 257-
1 p.
 artikel
135 Role of body build and temperament in children treated because of neurotic disorders Lintsi, M.
 1996
 6 Supplement 4 p. 12-
1 p.
 artikel
136 Role of inflammation, Apo E, and antichymotrypsin in Alzheimer's disease Potter, Huntington
 1996
 6 Supplement 4 p. S4-26-
1 p.
 artikel
137 Role of sigma receptors in motor control Walker, Michael J.
 1996
 6 Supplement 4 p. 159-
1 p.
 artikel
138 Role of the terminal 5-HT autoreceptor in the orbitofrontal cortex in the mechanism of action of 5-HT reuptake inhibitors in obsessive compulsive disorder Blier, P.
 1996
 6 Supplement 4 p. 91-
1 p.
 artikel
139 Social functioning and psychopathology of people in long-term psychiatric day care. Influence of new and classical neuroleptics on patient's outcome Nicolaou, S.
 1996
 6 Supplement 4 p. S4-116-
1 p.
 artikel
140 Specific cognitive deficits in schizophrenia Large, M.
 1996
 6 Supplement 4 p. 135-136
2 p.
 artikel
141 Stabilization of brain DA systems in psychosis by concomitant 5-HT2 and α2-receptor blockade Svensson, T.H.
 1996
 6 Supplement 4 p. 94-95
2 p.
 artikel
142 State-dependent immune disturbances in schizophrenia van Kammen, D.P.
 1996
 6 Supplement 4 p. 227-
1 p.
 artikel
143 Stress-induced phase-shifts inthe locomotor activity rhythm and increases in noradrenaline turnover inthe locus coeruleus region Tsujimaru, S.
 1996
 6 Supplement 4 p. 111-
1 p.
 artikel
144 Studies of cerebral blood flow with SPET and PET — Promises and pitfalls McGuire, P.K.
 1996
 6 Supplement 4 p. S4-8-S4-9
NaN p.
 artikel
145 Sustained 5HT2A receptor occupancy of ziprasidone using pet ligand 18F setoperone in healthy volunteers Fischman, A.
 1996
 6 Supplement 4 p. 177-
1 p.
 artikel
146 Synergistic increases of noradrenaline and 5-HT neurotransmission induced by milnacipran with pindolo Moret, C.
 1996
 6 Supplement 4 p. S4-68-
1 p.
 artikel
147 Synthetic CCK modulators: Update on current pharmacology Roques, B.P.
 1996
 6 Supplement 4 p. 214-
1 p.
 artikel
148 The analgetic activity of the new analog of ACTH (4–) fragment in patients with migraine attack Dubinin, V.A.
 1996
 6 Supplement 4 p. S4-156-S4-157
NaN p.
 artikel
149 The antinociceptive effect of fluvoxamine Schreiber, Shaul
 1996
 6 Supplement 4 p. 281-284
4 p.
 artikel
150 The bipolar nature of migrainous psychopathology Himlelhoch, J.
 1996
 6 Supplement 4 p. 27-
1 p.
 artikel
151 The effect of paroxetine and nefazodone on sleep: A placebo controlled trial Sharpley, A.L.
 1996
 6 Supplement 4 p. 139-
1 p.
 artikel
152 The effects of CCK-4 in normal individuals: Comparison of panickers and nonpanickers Koszycki, D.
 1996
 6 Supplement 4 p. 206-
1 p.
 artikel
153 The efficacy of sertraline in the treatment of major depression Bugarski-Kirola, D.
 1996
 6 Supplement 4 p. 124-
1 p.
 artikel
154 The functional neuroanatomy of prefrontal cortex: Implications for psychosurgery Geffen, L.B.
 1996
 6 Supplement 4 p. 230-
1 p.
 artikel
155 The neurodevelopmental hypothesis of schizophrenia: A critical clinical perspective Weinberger, D.R.
 1996
 6 Supplement 4 p. 169-
1 p.
 artikel
156 The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder van Megen, Harold J.G.M.
 1996
 6 Supplement 4 p. 187-194
8 p.
 artikel
157 The pharmacology of native NMDA receptor subtypes Carter, C.
 1996
 6 Supplement 4 p. S4-50-S4-51
NaN p.
 artikel
158 The place of cognitive therapy in the treatment of obsessive compulsive disorder van Oppen, P.
 1996
 6 Supplement 4 p. S4-16-
1 p.
 artikel
159 The role of cytochrome P450 2D6 in the metabolism of moclobemide Härtter, Sebastian
 1996
 6 Supplement 4 p. 225-230
6 p.
 artikel
160 The role of the seta adrenergic system in CCK-4 induced panic symptoms Le Mellédo, J.-M.
 1996
 6 Supplement 4 p. 114-
1 p.
 artikel
161 Treatment of anxiety disorders in rheumatic heart disease Khokhlov, A.
 1996
 6 Supplement 4 p. 15-
1 p.
 artikel
162 Treatment of social phobia with SSRIs Greist, J.H.
 1996
 6 Supplement 4 p. S4-38-S4-39
NaN p.
 artikel
163 Treatment of the neuroleptic malignant syndrome by electroconvulsive therapy Seifertová, Dagmar
 1996
 6 Supplement 4 p. 172-
1 p.
 artikel
164 Treatment options in refractory bipolar disorder, methodological problems and clinical opportunities Nolen, Willem A.
 1996
 6 Supplement 4 p. S4-31-
1 p.
 artikel
165 Type of onset and personality in panic disorder Hranov, L.
 1996
 6 Supplement 4 p. 205-
1 p.
 artikel
166 Ultra-rapid opioid detoxification using narcotic antagonists Kleber, H.D.
 1996
 6 Supplement 4 p. 162-
1 p.
 artikel
167 Use of benzodiazepines in opiate addicted patients — Results of an inquiry in basle Ladewig, D.
 1996
 6 Supplement 4 p. 2-
1 p.
 artikel
168 Use of combined SSRIS and moclobemide in treatment-resistant depression Grounds, D.
 1996
 6 Supplement 4 p. 127-
1 p.
 artikel
                             168 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland